Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 single-blind randomized placebo-controlled dose-escalation study of SLN124 in thalassemia and low-risk myelodysplastic syndrome
MOH_2021-04-29_009731Phase 2Active, not recruiting
- Sponsor
- Silence Therapeutics
- Start
- Apr 2021
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in alpha thalassemia, beta thalassemia and myelodysplastic syndrome (MDS) comparing SLN124 with Placebo (2 arms). Primary endpoints: Safety, Tolerability and 2 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
SLN124
03
Conditions
alpha thalassemiabeta thalassemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on MOH_2021-04-29_009731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-29_009731.